News

The discovery of this new microbe is not immediately concerning but warrants careful study,” Javier Martin-Torres, the University of Aberdeen, Scotland professor of planetary science, said in an ...
Nylon-6 Market Size Bio-based Nylon-6 is an emerging sustainable alternative, reducing carbon footprint while maintaining performance, resh ...
Key Trends and Growth Drivers in Isocoprostanol Biomarker Analysis Market Overview 2025: Size, Segmentation, and Leading Regions Technology Innovations: Advancements in Isocoprostanol Detection ...
As the U.S. market navigates a complex landscape with the S&P 500 experiencing slight declines and Treasury yields on the rise, investors are closely monitoring legislative developments that could ...
The demand for the widely used cancer drug Taxol is increasing, but it's difficult and expensive to produce because it hasn't ...
You can reach Jason on Signal at JasonMast.05. Prime Medicine, a biotech whose wild ambitions for a powerful gene editing technology sank as the biotech market slumped, announced Monday it is ...
Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...
We're going to check out a few of the best picks from our screener tool. Overview: Zhejiang Sunriver Culture Tourism Co., Ltd. operates in the cultural and tourism industry, focusing on developing ...
"These findings not only raise important considerations for planetary protection but also open the door for biotechnological innovation," said Junia Schultz, a postdoctoral fellow at KAUST who was ...
So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...
A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...